Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer
Locally Advanced Bladder Cancer
About this trial
This is an interventional treatment trial for Locally Advanced Bladder Cancer focused on measuring locally advanced bladder cancer, Postoperative radiotherapy, Adjuvant chemotherapy, Radical Cystectomy
Eligibility Criteria
Inclusion Criteria:
- Patients not more than 70 years old.
- Radical cystectomy performed within 42 days with no microscopic or macroscopic residual after surgery (negative surgical safety margins)
- Having one or more of the risk factors ( P3b,P4a,G3 and /or positive LN)
- ECOG Performance Scale (0-2).
- Adequate liver functions.
- Adequate renal function serum (creatinine < 1.5 mg).
- No evidence of distant metastasis or other malignancy.
Exclusion Criteria:
- patients who received radiotherapy or chemotherapy prior to radical cystectomy
Sites / Locations
- National cancer Institute-Cairo University
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Arm 1
Arm 2
Arm 3
post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy